Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody
AssigneeSeagen Inc.
InventorsLuke WALKER, Anita KULUKIAN
Life of this patent
Estimating the term…
Abstract
The invention provides methods of treating solid tumors, such as solid tumors with HER2 alterations, e.g., solid tumors in which HER2 is amplified/overexpressed or mutated, with a combination of tucatinib, or salt or solvate thereof, and at least one anti-HER2 antibody, such as trastuzumab or trastuzumab and pertuzumab.
Claims131
A method for treating a solid tumor in a subject comprising administering a combination of tucatinib, or salt or solvate thereof, and at least one anti-HER2 antibody to the subject, wherein the solid tumor has one or more HER2 alterations.
A method of increasing the overall amount of HER2 in a solid tumor comprising administering tucatinib, or salt or solvate thereof to a subject, wherein the administration of the tucatinib, or salt or solvate thereof, increases the overall amount of HER2 in the solid tumor.
A method of increasing the amount of plasma membrane-bound HER2 in a solid tumor comprising administering tucatinib, or salt or solvate thereof to a subject, wherein the administration of the tucatinib, or salt or solvate thereof, increases the amount of plasma membrane-bound HER2 in the solid tumor.
A method of increasing dwell time of HER2 at the cell surface of a solid tumor comprising administering tucatinib, or salt or solvate thereof to a subject, wherein the administration of the tucatinib, or salt or solvate thereof, increases the dwell time of HER2 at the cell surface.
A method of increasing internalization of plasma membrane-bound HER2 in a solid tumor comprising administering tucatinib, or salt or solvate thereof to a subject, wherein the administration of the tucatinib, or salt or solvate thereof, increases the internalization of plasma membrane-bound HER2.
A method of increasing lysosomal degradation of HER2 in a solid tumor comprising administering tucatinib, or salt or solvate thereof to a subject, wherein the administration of the tucatinib, or salt or solvate thereof, increases the lysosomal degradation of HER2.
Dependencies are inferred from the claim text.